Nexium Capsules Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome"
Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
Number of Adverse Drug Reactions, Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks|Number of Adverse Drug Reactions, Patients with duodenal ulcer: 6 weeks|Number of Adverse Drug Reactions, Patients with reflux oesophagitis: 8 weeks|Number of Adverse Drug Reactions, Patients with non-erosive reflux disease: 4 weeks
Nexium capsules Clinical Experience Investigation